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A B S T R A C T   
Plin5 is abundantly expressed in the heart where it binds to lipid droplets (LDs) and facilitates physical inter-
action between LDs and mitochondria. We isolated cardiomyocytes from adult Plin5+/+ and Plin5− /− mice to 
study the role of Plin5 for fatty acid uptake, LD accumulation, fatty acid oxidation, and tolerance to hypoxia. 
Cardiomyocytes isolated from Plin5− /− mice cultured with oleic acid stored less LDs than Plin5+/+, but com-
parable levels to Plin5+/+ cardiomyocytes when adipose triglyceride lipase activity was inhibited. The ability to 
oxidize fatty acids into CO2 was similar between Plin5+/+ and Plin5− /− cardiomyocytes, but Plin5− /− car-
diomyocytes had a transient increase in intracellular fatty acid oxidation intermediates. After pre-incubation 
with oleic acids, Plin5− /− cardiomyocytes retained a higher content of glycogen and showed improved toler-
ance to hypoxia compared to Plin5+/+. In isolated, perfused hearts, deletion of Plin5 had no important effect on 
ventricular pressures or infarct size after ischemia. Old Plin5− /− mice had reduced levels of cardiac tri-
acylglycerides, increased heart weight, and apart from modest elevated expression of mRNAs for beta myosin 
heavy chain Myh7 and the fatty acid transporter Cd36, other genes involved in fatty acid oxidation, glycogen 
metabolism and glucose utilization were essentially unchanged by removal of Plin5. Plin5 seems to facilitate 
cardiac LD storage primarily by repressing adipose triglyceride lipase activity without altering cardiac fatty acid 
oxidation capacity. Expression of Plin5 and cardiac LD content of isolated cardiomyocytes has little importance 
for tolerance to acute hypoxia and ischemia, which contrasts the protective role for Plin5 in mouse models during 
myocardial ischemia.   
Abbreviations: ATGL, adipose triglyceride lipase; BDM, 2,3-Butanedione monoxime; BSA, bovine serum albumin; Cpt1a/b, carnitine palmitoyltransferase 1a/b; 
Fabp3/4, fatty acid binding protein 3/4; FBS, fetal bovine serum; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Gbe1, glucan (1,4-alpha-) branching enzyme 1; 
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chain β isoform; Nppa/b, natriuretic peptide type A/B; OA, oleic acid; Pdha1, pyruvate dehydrogenase E1 alpha 1; Pdk4, pyruvate dehydrogenase kinase, isoenzyme 
4; Pygm, glycogen phosphorylase; RPP, rate pressure product; Rplp0, ribosomal protein lateral stalk subunit p0; Slc2a1/4, solute carrier family 2 member 1/4 (Glut1/ 
4); TAG, triacylglycerols; TLC, thin layer chromatography; TTC, triphenyl tetrazolium chloride. 
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1. Introduction 
Myocardial ischemia and infarction is a leading cause of death 
worldwide. Cardiac energy metabolism prior to and during acute 
myocardial ischemia may be important for the outcome and later clin-
ical complications [1–6]. The heart is able to use multiple energy sub-
strates, with substrate preference influenced by various physiological 
and pathophysiological conditions [7,8]. Normally, 60%–70% of car-
diac energy derives from oxidation of fatty acids, while the remaining 
energy is mainly generated from oxidation of glucose [9,10]. Notably, 
cardiomyocytes are equipped with reservoirs for these energy sub-
strates. Fatty acids are stored as triacylglycerol (TAG) in lipid droplets 
(LDs), and glucose is stored as glycogen. During acute myocardial 
ischemia, low oxygen levels inhibit aerobic fatty acid oxidation for 
generation of ATP through mitochondrial oxidative phosphorylation. 
Instead, the ischemic heart generates ATP primarily by glycolysis. Glu-
cosyl units mobilized from glycogen are converted to pyruvate, which is 
then converted into lactate to regenerate NAD+ to sustain glycolysis. 
However, during prolonged hypoxia, the accumulated lactate causes 
cellular acidification, reduced glycolytic rates, and eventually cell 
damage and cell death [11]. 
Cardiomyocytes take up glucose from the circulation, where gener-
ated glucose-6-phosphate is converted via glucose-1-phosphate into 
UDP-glucose that serves as building blocks for glycogen synthesis [12]. 
The final key steps in the glycogen synthesis pathway, and the initial 
step in the glycogen degradation pathways, are reciprocally regulated by 
various hormones in tissue-specific manners [13–15]. Liver and muscle 
serve as the main reservoirs for glycogen stores, which become mobi-
lized during stress, starvation and exercise. During these conditions, 
myocardium uses fatty acids as the main energy source and the cardiac 
glycogen is preserved or even increased [16,17]. The physiological/ 
pathological importance of the differently regulated cardiac glycogen 
storage is unclear. 
Circulating fatty acids taken up by cardiomyocytes are incorporated 
into TAG and stored in LDs to balance intracellular levels of free fatty 
acids. Formation of new and expansion of existing LD (esterification of 
lipids) and LD degradation (lipolysis or lipophagy) are tightly regulated 
processes [18]. These processes are regulated by proteins permanently 
or transiently recruited to the surface of LDs, such as LD-coating pro-
teins, lipid esterification enzymes, lipolytic factors and autophagosome 
recruiting proteins [19]. The perilipins constitute a major LD-coating 
protein family in mammals, consisting of the Plin1–5 genes that are 
expressed in a tissue-specific manner [20]. Of these, Plin5 is unique for 
mammals [21] and is highly expressed in oxidative tissues rich in 
mitochondria, such as the myocardium [22–24]. Mice lacking Plin5 
have reduced cardiac LD content [25], whereas mice with cardiac- 
specific Plin5 overexpression have increased cardiac LD content 
[26,27]. Plin5 facilitates physical interaction between LDs and mito-
chondria [28]. The significance of this interaction is unclear, but mito-
chondria interacting with LDs seem to have altered energy metabolism 
[29]. 
The role of LDs in ischemic heart disease is unclear. Accumulation of 
LDs in the myocardium has been observed in the boundary of an infarct 
area, in failing hearts, and in diabetic cardiomyopathy [30–32]. A few in 
vitro studies suggest that formation of LDs and enhanced TAG turnover 
in cardiomyocytes may protect against ischemia-reperfusion injury 
[4,33]. Cardiac overexpression of Plin5 increases LD content in the 
heart, causing slightly impaired cardiac mitochondrial function without 
affecting heart function [26]. In contrast, Plin5− /− mice with low levels 
of cardiac LDs have reduced survival after myocardial ischemia [34]. 
These studies show that cardiac LD storage can be manipulated by 
interfering with Plin5, but the consequences of such manipulation for 
cardiac energy metabolism is still unclear. The purpose of this study was 
to compare fatty acid uptake, LD accumulation, and fatty acid oxidation 
in cultured Plin5+/+ and Plin5− /− cardiomyocytes under normoxic and 
hypoxic conditions, as well as tolerance to ischemia in ex vivo perfused 
hearts. 
2. Materials and methods 
2.1. Reagents and materials 
Plasticware was obtained from Corning Life Sciences (Tewksbury, 
MA, US) and Sarstedt (Nümbrecht, Germany). Cell culture reagents and 
Bodipy 493/503 were obtained from Thermo Fisher Scientific (Wal-
tham, MA, US). 2,3-Butanedione monoxime (BDM), paraformaldehyde 
and Hoechst 33342 were obtained from Sigma-Aldrich (St. Louis, MO, 
US). Phalloidin-CF568 conjugate was from Biotium (Fremont, CA, US). 
[1-14C]-oleic acid and D-[14C(U)]-glucose were from PerkinElmer NEN 
(Boston, MA, US). Materials for real-time quantitative PCR were ob-
tained from Bio-Rad (Hercules, CA, US). 
2.2. Animal experiments 
Animal use in this study was approved and registered by the Nor-
wegian Animal Research Authority (Mattilsynet, approvals FOTS ids: 
#6305, #6922 and #10901) and confirmed to the ARRIVE guidelines 
and ethical guidelines given in Directive 2010/63/EU of the European 
Parliament on the protection of animals used for scientific purposes. 
Mice were housed with a stable light/dark cycle (7 am:7 pm) with 
55 ± 5% relative humidity at 22 ± 2 ◦C with free access to water and 
rodent chow (#RM3-801190, SDS diets, consisting of 12% calories from 
fat, 27% from protein, and 61% from carbohydrate). The health status of 
the animals was monitored quarterly and were absent of all pathogens 
listed by The Federation of European Laboratory Animal Science Asso-
ciations (FELASA). 
Generation of the Plin5 model is partially described previously [34]. 
Construction of the Plin5 targeting vector started with modifying the 
FRT sites in the p451 vector [35]. The new p451-Hygro-FRT5 vectror 
was generated by replacing the Neomycin resistant gene (neo) with the 
Hygromycin resistant gene (hph) followed by site directed mutagenesis 
of the two FRT sites in the p451-vector. Briefly, the hph gene was 
amplified from a vector (pcDNA5/FRT, Invitrogen), the PCR product 
digested with BspHI/Bcl I and ligated into NcoI/Bcl l digested pL451 
vector to generate a Hygromycin resistant gene cassette (p451-Hygro 
vector). Each FRT site was then sequentially mutated to FRT5 sites, 
which will not recombine with wild type FRT sites. The 5-end FRT site 
was mutated with PCR using the primer combination 5-pL451-FRT5 and 
3-pL451-Hygro, followed by ligation into XhoI and Bcl I digested p451- 
Hygro to generate p451-FRT5-Hygro-FRT. The 3-end FRT site was 
mutated using the primer combination 5-pL451-Hygro and 3-pL451- 
FRT5 followed by ligation into BspHI/Bcl I digested p451-FRT5-Hygro- 
FRT to generate p451-FRT5-Hygro-FRT5. Since the hph gene contains an 
EcoRI site, the cassette might be conveniently excised by XhoI/BamHI 
digestion. The new p451-Hygro-FRT5 vector was subsequently used to 
construct the Plin5 targeting vector using recombineering as described 
previously [35]. Details regarding construction of the targeting vector, 
electroporation of embryonic stem (ES) cells, Southern blot screening of 
ES cells, blastocyst injections, generation of chimera, verification of 
germline transmission, as well as all primers and oligoes used for 
Southern screening has been described previously [34]. 
The above Plin5 model [34] were crossed with mice expressing Flp 
[36] to remove the Hygromycin selection cassette (See Supplemental 
Fig. 1), followed by backcrossing for 10 generations into C57BL/6NRj 
(Janvier Labs, Le Genest-Saint-Isle, France). Experimental Plin5 wild 
type (Plin5+/+) and Plin5 null (Plin5− /− ) animals were from the same 
breeding colony. For tissue collection, mice were euthanized by cervical 
dislocation at 8 am – 10 am. For ex vivo heart perfusion and car-
diomyocyte isolation, an intraperitoneal injection of 50 μg/g body 
weight sodium pentobarbital solution containing 8 IU/g body weight 
heparin was given to mice prior to euthanasia by cervical dislocation 
and collection of hearts. The majority of experiments were performed in 
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animals at 18–30 weeks of age. The number of animals used is stated for 
each animal experiment. None of the animals used have been excluded 
from analysis. In total, 45 Plin5+/+ and 45 Plin5− /− mice were used in 
these studies. 
2.3. Ischemia-reperfusion in ex vivo perfused Langendorff mouse heart 
Mice were anesthetized and heparinized as described above. The 
hearts were quickly isolated, the aorta cannulated, then hearts were 
connected to a Langendorff system (AD Instruments, NSW, Australia) 
and retrogradely perfused with Krebs-Henseleit buffer (11.1 mM 
Glucose, 118.5 mM NaCl, 25 mM NaHCO3, 4.7 mM KCl, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, and 2.4 mM CaCl2) during constant bubbling 
with 95% O2/5% CO2 gas. Perfusion pressure was constant at 70 mmHg 
and temperature (37 ◦C) was monitored with a probe inside the right 
atrium. Heart rate, left ventricular systolic pressure (LVSP) and end- 
diastolic pressure (LVEDP) were recorded by a pressure transducer 
connected to a water-filled balloon in the left-ventricle. LVEDP was 
maintained at 5–10 mm Hg during stabilization. Left ventricular devel-
oped pressure (LVdevP = LVSP − LVEDP) and rate pressure product 
(RPP) were calculated by Labchart 7 software (ADInstruments, Dunedin, 
New Zealand). Exclusion criteria after 20 min of stabilization were: 
hearts with LVSP ≤ 60 mmHg; coronary flow ≤ 1 mL/min or ≥ 5 ml/ 
min; heart rate ≤ 220 beats/min; time delay >4 min from heart excision 
to start of perfusion or irreversible arrhythmias during stabilization. The 
hearts included were subjected to 35 min of no-flow global ischemia 
followed by 60 min of reperfusion. 
At the end of reperfusion, hearts were sliced (1 mm thick cross sec-
tions) and stained with 1% triphenyl tetrazolium chloride (TTC, dis-
solved in PBS) at 37 ◦C for 15 min for assessment of infarct size. The five 
middle slices of the heart were acquired with an Epson Perfection V700 
scanner (Epson, Suwa, Japan) and blindly analyzed by Image Analyzer 
plugin of Science Linker B000 database (Science Linker AS, Oslo, Nor-
way). Infarct size was calculated as average percentage of infarct areas 
in whole heart sections. 
2.4. Isolation and stimulation of cardiomyocytes 
Cardiomyocytes were isolated based on the method described by 
O’Connell et al. [37]. Briefly, mice were anesthetized and heparinized 
prior to cervical dislocation. Hearts were quickly connected to the 
perfusion system and perfused at 37 ◦C for 4 min with constant flow 
(4 mL/min) of perfusion buffer (120.4 mM NaCl, 14.7 mM KCl, 0.6 mM 
KH2PO4, 0.6 mM Na2HPO4, 1.2 mM MgSO4, 10 mM Na-HEPES, 4.6 mM 
NaCO3, 30 mM taurine, 10 mM 2,3-Butanedione monoxime (BDM) and 
5.5 mM glucose, pH 7.0) to flush out blood. Thereafter, the heart was 
perfusion with 15 mL recirculating digestion buffer (perfusion buffer 
containing 1.33 mg/mL Collagenase II (#4177, Worthington Biochem-
ical; Lakewood, NJ, US)) to digest extracellular matrix. After 3 min, 
CaCl2 was added to the digestion buffer to achieve a final concentration 
of 42 μM, followed by 8 min of digestion. Then hearts were disrupted 
mechanically with sharp forceps in a six-cm petri dish containing 10 mL 
buffer A (perfusion buffer supplemented with 10% FBS and 12.5 μM 
CaCl2) and transferred to a 15 mL conical tube. Cells were dissociated by 
gently pipetting for 3–4 min. Undigested chunks were removed from the 
cell suspension, and centrifuged at 20 ×g for 3 min to spin down car-
diomyocytes. The cardiomyocyte pellet was resuspended in 10 mL 
buffer A and centrifuged again, followed by gradient reintroduction of 
calcium by repeating suspension and centrifugation in 10 mL perfusion 
buffer supplemented with 10% FBS, containing 100 μM (buffer B), 
400 μM (buffer C) or 900 μM (buffer D) CaCl2. After calcium reintro-
duction, cardiomyocytes were resuspended in plating medium (Mini-
mum Essential Medium with Hank’s balanced salt solution, 
supplemented with 10% fetal calf serum, 10 mM BDM, 100 U/mL 
penicillin and 2 mM glutamine) and seeded in laminin (1 μg/cm2, 
#354232, BD Biosciences; East Rutherford, NJ, US) coated multiple well 
plates (Corning Life Sciences, Tewksbury, MA, US) or 8-well chamber 
slides (# 94.6170.802, Sarstedt; Nümbrecht, Germany). Car-
diomyocytes were allowed to recover and attach for 1–2 h at 37 ◦C under 
2% CO2. Plating medium was replaced by serum-free short-term me-
dium (Minimum Essential Medium with Hank’s balanced salt solution, 
containing 1 mM BDM, 100 U/mL penicillin and 2 mM glutamine) sup-
plemented with 40 μM bovine serum albumin (BSA, control) or oleic 
acid (OA) complexed to BSA (100 μM OA: 40 μM BSA, referred as OA in 
the following), vehicle (DMSO) or 10 μM Agtlistatin (ATGL inhibitor). 
Depending on downstream analyses, cardiomyocytes were stimulated 
for 2–20 h and maintained undisturbed at 37 ◦C under 2% CO2 and at-
mospheric O2 until use. 
2.5. Confocal imaging of cardiomyocytes 
Cardiomyocytes plated in 8-well chamber slides were incubated with 
serum-free short-term medium and stimulated with vehicle, BSA, OA, 
and/or Atglistatin. After 20 h of incubation, cells were washed once with 
Dulbecco’s Phosphate-Buffered Saline, fixed with 4% PFA in 0.1 M 
phosphate buffer pH 7.4 (PB) for 1 h at room temperature, washed twice 
with PB and stored in PB containing 0.02% NaN3 at 4 ◦C until staining. 
Cells were washed twice with PB and stained for 20 min at room tem-
perature with PB containing Bodipy 493/503 (1 μM for LDs), Hoechst 
33342 (5 μM for nuclei) and CF568 conjugated Phalloidin (1 U/mL for F- 
actin). After three washes with PB, cells were sealed in mounting me-
dium (#P36965, Thermo Fisher Scientific; Waltham, MA, US) under 
glass coverslips and stored in the dark at room temperature for 24 h to 
allow hardening of mounting medium. Images were taken under 20×
and 63× objectives on a LSM 710 confocal microscope (Carl Zeiss, 
Oberkochen, Germany). Microscopy laser and filter settings for all 
channels were optimized for a representative field and kept constant 
during image acquisition (Bodipy 493/503: λex = 488 nm, 
λem = 497–545 nm; Hoechst: λex = 405 nm, λem = 414–465 nm; 
Phalloidin-CF568: λex = 561 nm, λem = 563–632 nm). 
2.6. Hypoxia-reoxygenation in cardiomyocytes and cell damage 
assessments 
Cardiomyocytes plated in 12-well dishes were incubated in serum- 
free short-term medium containing vehicle, BSA, OA and/or Atglista-
tin for 16 h. Cells were then exposed to hypoxia by changing to pre- 
equilibrated hypoxic medium (glucose-free short-term medium, 
pH 6.4) and incubated in a hypoxia chamber (#856-HYPO, Plas Labs; 
Lansing, MI, US) at 1% O2, 5% CO2, 37 ◦C for 30 min. Reoxygenation 
was induced by changing to normoxic pre-equilibrated short-term me-
dium (5.5 mM glucose, pH 7.4) followed by incubation under normoxic 
condition (2% CO2, atmospheric O2, 37 ◦C) for 20 min. Normoxic con-
trol groups were subjected to the same media change intervals but were 
given pre-equilibrated short-term medium and incubated under nor-
moxic conditions. Conditioned medium was harvested at the end of each 
step and centrifuged at 3000 ×g for 5 min to remove cell debris. Cells 
were collected with lysis buffer after reoxygenation. Samples were kept 
at 4 ◦C and analyzed within 48 h. 
To estimate damage of cardiomyocytes, concentration of released 
lactate dehydrogenase (LDH) was measured with LDH Cytotoxicity 
Detection Kit (#11644793001, Roche; Mannheim, Germany). Reaction 
absorbance was measured at 492 nm by a microplate reader (Titertek 
Multiskan PLUS MK II, Thermo Labsystems, Thermo Fisher Scientific; 
Waltham, MA, US). Total LDH was calculated as the sum of LDH release 
during pre-incubation, hypoxia/normoxic control and reoxygenation 
steps and the remaining LDH in the cell lysate. 
2.7. Measuring flux of energy substrates in isolated cardiomyocytes 
To monitor the flux of energy substrates in Plin5+/+ and Plin5− /−
cardiomyocytes, [1-14C]-oleic acid (OA) and D-[14C(U)]-glucose (both 
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with activity 1 μCi/mL) were added as tracers to serum-free short-term 
media. Unlabeled OA or glucose were added to achieve the indicated 
total (labeled+ unlabeled) substrate concentrations. Cardiomyocytes 
seeded in four parallel 96-well plates (six parallels for each condition) 
were given serum-free short-term medium (150 μL/well) and stimulated 
with BSA (control) or OA (100 μM bound to BSA) in the presence of 
DMSO (vehicle) or Atglistatin (10 μM). Three plates were incubated in 
the presence of tracers for 2, 6 or 20 h. The fourth plate was incubated in 
the absence of tracers for 18 h, then with tracer for 2 h. All plates were 
mounted with a trapping device (see section below) to capture CO2 
released by the cells during the last 2 h of incubation. At the end of the 
experiment, the culture media was collected and centrifuged at 3000 ×g 
for 5 min to remove cell debris. Cardiomyocytes were washed once with 
0.2% BSA in PBS, followed by two washes with cold PBS to remove 
membrane bound tracers from the cell surface. Finally, cells were lysed 
in 100 μL 0.1 M NaOH. Plates containing cell lysates were sealed with 
parafilm and stored in − 20 ◦C until counting of radioactivity and mea-
surement of proteins. 14C radioactivity in trapped CO2, cell lysates, acid 
soluble metabolite fractions and conditioned media was determined to 
calculate metabolic flux. 
Trapping of CO2. 
To measure complete oxidation of OA or glucose, CO2 released 
during the last 2 h of incubation was trapped in a filter according to 
Wensaas et al. [38] with minor modifications. Briefly, a UniFilter-96 GF/ 
B plate (#6005177, PerkinElmer; Shelton, CT, US) was immersed with 
fresh 1 M NaOH (30 μL/well) and inversely fixed on top of a 96-well 
plate containing cardiomyocytes. A 96-orifice silicon gasket was 
placed between the filter plate and 96-well plate to seal the sandwich 
and separate individual wells. The trapping sandwich was kept sealed 
for 2 h at 37 ◦C where released CO2 was absorbed by the NaOH- 
immersed filters. After trapping, 30 μl/well of Optiphase supermix 
scintillation cocktail (#1200–439, PerkinElmer; Shelton, CT, US) was 
added to the filter plates. Plates were sealed with TopSeal-A PLUS 
(#6050185, PerkinElmer; Shelton, CT, US) prior to measurement of 
radioactivity. 
2.8. Acid soluble metabolites 
To measure acid soluble metabolites, cell lysates (30 μl/well) were 
transferred to a 96-well microtube plate (#721978202, Sarstedt; Nüm-
brecht, Germany). To precipitate medium to long chain fatty acids (>
C6), fatty acid-free bovine serum albumin (10 μL/well) was mixed with 
the cell lysate, followed by addition of cold 1 M HClO4 (100 μL/well). 
The plate was incubated at 4 ◦C for 30 min and then centrifuged at 
3500 ×g for 10 min at 4 ◦C. A fraction of the supernatant (40 μL, con-
taining acid soluble metabolites) was carefully collected without dis-
turbing the precipitate. 
2.9. Measurement of radioactivity and calculations 
Radioactivity in UniFilter-96 GF/B filter plates (trapped CO2) was 
measured after two days with a Packard Top Count Microplate Scintil-
lation Counter (PerkinElmer, Shelton, CT, US). For determination of 
radioactivity in the media, cell lysates and acid soluble metabolite 
fractions, two wells were combined (resulting in three replicates for 
each condition. 40 μL were transferred to a white Barex opaque 96-well 
microplate (#6005162, PerkinElmer; Shelton, CT, US) and mixed with 
120 μL/well Optiphase supermix (#1200–439, PerkinElmer; Shelton, 
CT, US). Plates were sealed with TopSeal-A PLUS and top-counted for 
3 min per well. Specific activity (counts per minute (CPM)/nmol of 14C- 
labeled or total substrate) was calculated based on measured CPM for 
unconditioned media. Protein content in cell lysates (20 μL cell lysate) 
were measured with BCA protein assay kit (#23227, Pierce Biotech-
nology; Rockford, IL, US). Data for uptake or metabolism of OA and 
glucose are presented as μmol substrate/L for media, or nmol substrate/ 
mg protein for cell lysates, acid soluble fractions and CO2. 
2.10. Determination of glycogen and triacylglycerol content 
Glycogen and TAG content was normalized to protein content. Pro-
tein content in homogenates described below was measured with BCA 
protein assay kit (Pierce, Rockford, IL, US). Glycogen was determined 
with EnzyChrom Glycogen Assay Kit (# E2GN-100, BioAssay Systems; 
Hayward, CA, US). Powdered frozen heart tissue (~15 mg) or isolated 
cardiomyocytes (seeded in 6-well plates, stimulated as described above 
and washed twice in cold PBS) were harvested in 250 μl glycogen buffer 
(containing 25 mM citrate and 2.5 g/L NaF, pH 4.2). Samples were 
transferred to micro tubes containing 10–15 glass beads (~1 mm in 
diameter) and homogenized using Precellys 24 tissue homogenizer 
(Bertin Technologies; Montigny-le-Bretonneux, France). The homoge-
nate (100 μL) was centrifuged at 14,000 ×g for 5 min to remove debris. 
Samples (10 μL) or glycogen standards were separately mixed with 90 μL 
working reagent and incubated at room temperature for 30 min. Fluo-
rescence was measured with BioTek Synergy H1 microplate reader 
(λex = 530 nm, λem = 585 nm). 
Triglyceride content in heart tissue was quantified with thin layer 
chromatography (TLC). Tissue was homogenized in PBS with glass beads 
using a Precellys 24 tissue homogenizer (Bertin Technologies; Montigny- 
le-Bretonneux, France). Total lipids were extracted from the tissue ho-
mogenate (120 μg protein, 100 μL) by mixing with 200 μL of chloroform: 
heptane:methanol (4:3:2, v/v) followed by vigorously vortex for 2 × 15 
seconds. The liquid phases were separated at room temperature for 
>15 min prior to centrifugation at 1200 ×g for 5 min. The lower organic 
phase was evaporated under N2 for 5 min and lipids dissolved in 30 μL 
chloroform:methanol (2:1, v/v). TLC was performed on silica gel 60 
plates (Merck Millipore, Billerica, MA) as described previously [39]. TLC 
plates were scanned with Epson Perfection V700 scanner (Epson; Suwa, 
Japan). Images were analyzed with ImageJ and concentrations were 
calculated against a TAG standard curve run in parallel. 
2.11. RNA extraction and gene expression analysis 
Total RNA was extracted with NucleoSpin® RNA kit (MACHEREY- 
NAGEL, GmbH & Co. KG; Düren, Germany). Frozen heart tissue 
(~10 mg) was powdered, transferred to micro tubes containing 10–15 
glass beads and homogenized in RA1 buffer using Precellys 24 tissue 
homogenizer (Bertin Technologies; Montigny-le-Bretonneux, France). 
Cultured cardiomyocytes were washed once with PBS before harvested 
in RA1 lysis buffer. Concentrations and quality of extracted RNA were 
determined with a Nano-Drop ND-1000 Spectrophotometer (Thermo 
Scientific; Waltham, MA, US). 
Total RNA (300 ng) was reversely transcribed into cDNA with High- 
Capacity cDNA Reverse Transcription Kit (MultiScribe). Gene-specific 
regions (70–120 bp) were amplified from cDNA (7.5 ng) with assay 
primers (100 nM each) and SsoAdvanced™ Universal SYBR® Green 
Supermix (Bio-Rad; CA, US) on the ABI 7900HT system (10 μL reaction, 
95 ◦C for 3 min, followed by 40 cycles; 95 ◦C for 10 s and 60 ◦C for 20 s). 
Primers (listed in Table 1) were designed using Primer-BLAST software. 
Ribosomal protein lateral stalk subunit P0 (Rplp0) and Glyceraldehyde 
3-phosphate dehydrogenase (Gapdh) mRNAs were verified to be stably 
expressed and were used as reference genes for cardiomyocytes and 
tissues, respectively. All data was analyzed with relative quantification 
(ΔΔCt method) and was presented as gene expression relative to 
endogenous controls (2-∆∆Ct). 
2.12. Statistics 
All data were analyzed with Prism 5 (Graphpad Software; CA, US). 
Parameters reflecting heart function in Langendorff experiments and 
glycogen measurements were analyzed with two-way ANOVA with 
Tukey’s post-hoc tests. Two tailed Student’s t-test was used to analyze 
remaining data. p <0.05 was defined as significant, while a p-value 
between 0.05 and 0.1 was considered as having a tendency of difference. 
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Data in graphs are shown as means ± SD, or means ± SEM. 
3. Results 
3.1. Expression of Plins and storage of lipid droplets in isolated 
cardiomyocytes 
Plin5 is expressed at low levels in most cultured cells [40], which 
precludes functional mechanistic in vitro studies on Plin5 function and 
its effect on energy metabolism. To evaluate if isolated cardiomyocytes 
are a suitable model to study the metabolic role of Plin5, we first 
determined Plin5 mRNA in Plin5+/+ and Plin5− /− cardiomyocytes 
maintained in culture for up to 20 h. After isolation and one-hour re-
covery and attachment to laminin (denoted as 0 h), levels of Plin5 mRNA 
in Plin5+/+ cardiomyocytes were comparable to those of heart tissue 
(Fig. 1A). This indicates that the cardiomyocyte isolation procedure did 
not affect Plin5 mRNA levels. When cardiomyocytes were cultured for 
20 h in serum-free media in the presence of BSA, Plin5 mRNA expression 
reduced significantly, but were still expression significantly (Fig. 1A). 
Although increased fatty acid concentrations will often stimulate tran-
scription of Plin5 [40], addition of physiological levels of OA was unable 
to maintain Plin5 mRNA expression in cultured cardiomyocytes. As ex-
pected, we confirmed that Plin5 transcripts were undetectable in either 
cardiomyocytes or heart tissue from Plin5− /− mice. 
Plin5 deletion did not influence mRNA levels of Plin-family members 
Plin2–4 (Fig. 1A). While culturing cardiomyocytes in the absence of OA 
for 20 h reduced Plin2 mRNA levels ~50% compared to heart tissue, 
incubation with OA increased Plin2 mRNA levels. Plin3 mRNA was 
reduced moderately after 20 h, with minimal effect of OA. Plin4 mRNA 
decreased ~80% after 20 h compared to heart tissue, but OA partly 
attenuated this decrease. 
To compare LD storage ability, Plin5+/+ and Plin5− /− car-
diomyocytes were stained with Bodipy 493/503, Hoechst 33342 and 
Phalloidin-CF568 to visualize LDs, nuclei and the myofibrils, respec-
tively. None or very few LDs were visible in Plin5+/+ or Plin5− /− car-
diomyocytes cultured without OA (Fig. 1B), regardless of the presence of 
Atglistatin, an inhibitor of adipose triglyceride lipase (ATGL, the pri-
mary triglyceride lipase in heart [41]). When cardiomyocytes were 
incubated with OA, numerous LDs were observed in Plin5+/+ car-
diomyocytes, whereas Plin5− /− cardiomyocytes still contained few LDs 
(Fig. 1B). However, when OA stimulation was combined with Atglista-
tin, Plin5+/+ and Plin5− /− cardiomyocytes accumulated comparable 
levels of LDs, at levels above those observed for cardiomyocytes incu-
bated with OA alone (Fig. 1B). Clearly, Plin5 is required for LD storage in 
cardiomyocytes. Taken together, isolated cardiomyocytes appear to be a 
suitable model to study Plin5 function and the importance of LD storage 
for myocardial metabolism. 
Accumulation and utilization of fatty acid and glucose in Plin5+/+
and Plin5− /− cardiomyocytes. 
To determine if the presence of cardiac LDs may alter utilization of 
fatty acids and glucose [39], we studied the metabolic profiles of Plin5+/ 
+ and Plin5− /− cardiomyocytes using 14C-labeled oleic acid and glucose. 
When cardiomyocytes were incubated with 100 μM OA, the levels of OA 
in the media declined by ~50% after 20 h of incubation, independent of 
the Plin5 genotype or the presence of Atglistatin (Fig. 2A). However, 
compared to Plin5+/+ cardiomyocytes, Plin5− /− cardiomyocytes had 
reduced intracellular storage of OA (Fig. 2B). The difference in OA 
accumulation between Plin5+/+ and Plin5− /− cardiomyocytes was 
already evident after 2 h and stabilized by 6 h. In contrast, when ATGL 
activity was inhibited, accumulation of OA was similar in Plin5+/+ and 
Plin5− /− cardiomyocytes and significantly increased compared to cells 
cultured without Atglistatin (Fig. 2B). 
Acid soluble metabolites representing various short (<6 carbons) 
metabolic intermediates formed during fatty acid oxidation [42,43] are 
measurements of incompletely oxidized fatty acids. The levels of these 
metabolites were unchanged from two to 20 h in OA-stimulated Plin5+/+
cardiomyocytes. In contrast, these metabolites increased transiently in 
OA-stimulated Plin5− /− cardiomyocytes after 2 h and peaked at 6 h 
(Fig. 2C). The transient increase of acid soluble metabolites was 
inhibited by Atglistatin. This suggests that incomplete fatty acid oxida-
tion differs between Plin5+/+ and Plin5− /− cardiomyocytes, at least 
during the early phase of incubation. 
We then moved on to study complete oxidation of fatty acids into 
CO2. Previous studies determining fatty acid oxidation in cells or tissues 
lacking or overexpressing Plin5 are not fully conclusive [25,44–48]. In 
the majority of these studies, 14CO2 derived from [1-14C]-fatty acids was 
measured to calculate the amount of fatty acids completely oxidized into 
CO2 [49]. To test if labelling conditions influenced such 14CO2 mea-
surements, we pre-incubated cardiomyocytes with OA for 18 h, and then 
incubated with 14C-OA for 2 h while trapping CO2. Alternatively, 
Table 1 
Primers used for RT-qPCR in this study.  
Gene name Accession Forward primer Reverse primer Product size Intron length 
Cd36 NM_001159557.1 AGGCATTCTCATGCCAGTCG TGTACACAGTGGTGCCTGTT  119  8174 
Cpt1a NM_013495.2 CCCAGCTGTCAAAGATACCGT GCTGTCATGCGTTGGAAGTC  84  3807 
Cpt1b NM_009948.2 CCCTCATGGTGAACAGCAACT GCATTGCCTAGACGGGCTG  85  1095 
Fabp3 NM_010174.1 GGACAGCAAGAATTTTGATGACTAC TTGGTCATGCTAGCCACCTG  78  3440 
Fabp4 NM_024406.2 GGGAACCTGGAAGCTTGTCTC CCACTTTCCTTGTGGCAAAGC  83  2316 
Gapdh NM_001289726.1 GGTCCCAGCTTAGGTTCATCAG AAATCCGTTCACACCGACCTT  87  1082 
Gbe1 NM_028803.4 ATGATTCGTCTCATCACTCACG CCATTCAGGATGCCCAAACT  81  31,717 
Gyg NM_013755.3 GCATCTGGCTTCTGAGCAA TTGCCCAGCCACTAAAATATGTA  77  12,395 
Gys1 NM_030678.3 TTGGGGTCTTCCCCTCCTAC GTGGAGATGCTGGGGATGC  82  3183 
Hk1 NM_010438.3 GGACCACAGTTGGCGTAGA CTCAGGGTCTTGTGGAACCG  76  3507 
Hk2 NM_013820.3 CTTCCCTTGCCAGCAGAACA TGACCACATCTTCACCCTCG  95  2651 
Myh6 NM_001164171.1 TGCGCATTGAGTTCAAGAAGAT TGAAGGCCCGAATGTTCCAC  75  2548 
Myh7 NM_080728.2 CTGACGCAGGAGAGCATCAT CAATCCTGGCATTGAGTGCAT  103  1754 
Nppa NM_008725.3 CTTCGGGGGTAGGATTGACA ATCGACTGCCTTTTCCTCCTT  99  390 
Nppb NM_008726.5 GCTGCTTTGGGCACAAGATA AGCCAGGAGGTCTTCCTACAA  89  443 
Pdha1 NM_008810.3 CGTGGTTTCTGTCACTTGTGTG CGTAGGGTTTATGCCAGCCT  72  1833 
Pdk4 NM_013743.2 AAGATGCTCTGCGACCAGTA CAATGTGGATTGGTTGGCCTG  91  1858 
Plin2 NM_007408.3 GGGCTAGACAGGATGGAGGA CACATCCTTCGCCCCAGTTA  99  2215 
Plin3 NM_025836.3 CGAAGCTCAAGCTGCTATGG TCACCATCCCATACGTGGAAC  98  1147 
Plin4 NM_020568.3 ACCAACTCACAGATGGCAGG AGGCATCTTCACTGCTGGTC  109  1213 
Plin5 NM_001077348.1 GGTGAAGACACCACCCTAGC CCACCACTCGATTCACCACA  115  568 
Pygm NM_011224.2 GAGTGGAGGACGTGGAAAGG CCGAAGCTCAGGAATTCGGT  77  3654 
Rplp0 NM_007475.5 TGCACTCTCGCTTTCTGGA GCGCTTGTACCCATTGATGATG  110  907 
Slc2a1 NM_011400.3 CTCGGATCACTGCAGTTCGG CGTAGCGGTGGTTCCATGTT  97  11,636 
Slc2a4 NM_009204.2 CGACGGACACTCCATCTGTT ACATAGCTCATGGCTGGAACC  104  524  
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cardiomyocytes were incubated with 14C-OA for the entire 20 h with 
trapping of CO2 during the last 2 h. The captured 14CO2 was lower in 
cardiomyocytes incubated with 14C-OA only for the two last hours 
(Fig. 2D). This observation suggests that a relatively large fraction of 
captured CO2 originates from fatty acids stored in LDs. Furthermore, 
captured 14CO2 was ~50% higher in Plin5− /− compared to Plin5+/+
cardiomyocytes incubated with 14C-OA only for the two last hours, 
whereas captured 14CO2 was similar in Plin5+/+ and Plin5− /− car-
diomyocytes incubated with 14C-OA in the 20 h incubation period. These 
findings demonstrate that labelling conditions, including differences in 
LD content, may affect the experimental outcome (Fig. 2E), which may 
explain the controversies regarding the role of Plin5 for fatty acid 
oxidation. Based on these data, we chose to incubate cardiomyocytes 
with 14C-OA from 0 to 20 h and trap 14CO2 at different time points to 
determine complete fatty acid oxidation. When cardiomyocytes were 
incubated in the presence of 14C-OA, calculated total CO2 production 
peaked at 4–6 h (Fig. 2F). There was no obvious difference in CO2 pro-
duction between Plin5+/+ and Plin5− /− cardiomyocytes at any of the 
measured time points. Atglistatin had no evident effect on CO2 
production in Plin5− /− cardiomyocytes, but CO2 captured from Plin5+/+
cardiomyocytes was slightly reduced (Fig. 2F). 
We also examined if Plin5 deletion influenced glucose oxidation. 
Levels of 14C-glucose in the media were stable during the 20 h of incu-
bation. Cellular accumulation of 14C-glucose was not affected by geno-
type (Supplemental Fig. 2B). Production of 14CO2 derived from 14C- 
glucose tended to be reduced in Plin5+/+ and Plin5− /− cardiomyocytes in 
the presence of OA, indicating that fatty acids may repress glucose 
oxidation. No significant difference in glucose oxidation was noticed 
between Plin5+/+ and Plin5− /− cardiomyocytes in any groups (Supple-
mental Fig. 2C), suggesting that Plin5 had no clear effect on glucose 
oxidation in isolated cardiomyocytes. 
Oleic acid increased tolerance to hypoxia in Plin5− /−
cardiomyocytes. 
Previous reports suggest that accumulation of LDs may be protective 
during hypoxia and ischemia [33,50,51]. We thus studied the effects of 
hypoxia on cardiomyocytes with or without accumulated LDs. Cell 
damage was assayed by measurement of released lactate dehydrogenase 
(LDH) [52]. Under standard normoxic culturing conditions, little 
Fig. 1. mRNA expression of Plin2–5 and LD storage in isolated cardiomyocytes. 
Female Plin5+/+ and Plin5− /− mice (16 weeks) with ad libitum access to chow were used for extraction of heart tissue or isolation of cardiomyocytes. Cardiomyocytes 
right after attachment are denoted as 0 h. Cardiomyocytes further incubated for 20 h in the presence of BSA control or 100 μM oleic acid complexed to BSA are 
denoted as 20 h BSA and 20 h OA, respectively. 
A) Relative mRNA expression of Plin2–5 in heart tissue and isolated cardiomyocytes. mRNA data normalized to Gapdh is presented as means ± SD (n = 4, *p < 0.05 
indicate differences compared to heart tissue; #p<0.05 indicate differences between BSA and OA at 20 h of incubation). 
B) LD storage in isolated Plin5+/+ and Plin5− /− cardiomyocytes. Cardiomyocytes were incubated for 20 h in media supplemented with BSA or BSA-bound oleic acid 
(100 μM) in the presence of vehicle (DMSO) or Atglistatin (10 μM). Cells were fixed and stained with Bodipy493/503 to visualize lipid droplets (yellow-green), 
Hoechst33342 to visualize nuclei (blue), and CF568-Phalloidin to visualize F-actin (red). 
Confocal pictures of representative cardiomyocytes taken under a 63× oil immersion objective are shown. Scale bar is 20 μm. Abbreviations: Gapdh, Glyceraldehyde 
3-phosphate dehydrogenase; BSA, bovine serum albumin; OA, oleic acid; N.D., not detected. 
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difference was observed between Plin5+/+ and Plin5− /− cardiomyocytes, 
regardless of the OA concentration in the culture media or prevention of 
lipolysis with Atglistatin (Fig. 3A). Then, Plin5+/+ and Plin5− /− car-
diomyocytes were incubated in media supplemented with BSA, OA, or 
OA combined with Atglistatin for 16 h prior to acute hypoxia followed 
by reoxygenation. Cell damage was similar in Plin5+/+ and Plin5− /−
cardiomyocytes cultured in serum free media, but contradictory to 
previous studies [25,33,34], pre-incubation with OA reduced damage of 
Plin5− /− cardiomyocytes (Fig. 3B). Hypoxia caused similar damage in 
Plin5+/+ and Plin5− /− cardiomyocytes incubated with OA in the pres-
ence of Atglistatin. Previous studies have linked higher glycogen content 
to improved outcome after myocardial ischemia [53]. We thus measured 
glycogen content in cardiomoycytes prior to hypoxic exposure. 
Glycogen levels were similar in Plin5+/+ and Plin5− /− cardiomyocytes 
incubated with BSA or Atglistatin for 16 h (Fig. 3C). When incubated 
with OA, glycogen content was higher in Plin5− /− cardiomyocytes 
compared to Plin5+/+, whereas levels were significantly reduced in OA 
and Atglistatin incubated Plin5+/+ and Plin5− /− cardiomyocytes. These 
results point to alterations in energy sources in OA stimulated Plin5− /−
cardiomyocytes. 
3.2. Deletion of Plin5 did not influence infarct size in isolated, perfused 
mouse hearts 
To follow up our findings in isolated cardiomyocytes, we investi-
gated the effect of Plin5 deletion on ischemia-reperfusion injury in iso-
lated, perfused hearts supplemented with glucose as the main energy 
substrate. There was no important difference in heart function (LVSP, 
LVEDP, LVdevP and RPP) or infarct size between isolated, perfused 
hearts from Plin5+/+ and Plin5− /− mice (Fig. 4A, B, C, E and F). During 
reperfusion, heart rate was lower in Plin5− /− hearts (Fig. 4D), suggesting 
a chronotropic effect of Plin5 deletion. The less significant role of Plin5 
during hypoxia in our in vitro cultured cardiomyocyte model (Fig. 3) and 
ex vivo perfused heart model (Fig. 4) are inconsistent with the role of 
Plin5 during myocardial infarction in vivo, where Plin5− /− mice have 
increased infarct size and higher mortality [34,61]. 
Plin5− /− mice had increased heart weight with age and mild changes 
in cardiac metabolism. 
Heart function of Plin5− /− mice may decrease with age [25]. 
Therefore, we compared hearts from young (15 weeks) and aged 
(55 weeks) Plin5+/+ and Plin5− /− mice. Body weights were similar at the 
Fig. 2. Metabolism of oleic acid in Plin5+/+ and Plin5− /− cardiomyocytes. 
Cardiomyocytes isolated from female Plin5+/+ and Plin5− /− mice (22 weeks females) were incubated with 100 μM OA (unlabeled OA + [1-14C]-OA = 100 μM) bound 
to BSA in the presence of vehicle (OA) or 10 μM Atglistatin (OAþAtglistatin). Radioactivity in conditioned media, cell lysate, cellular acid soluble metabolites, and 
released CO2 was measured to determine fatty acid flux. 
A) OA in conditional media during incubation. 
B) Cellular accumulation of OA. 
C) Cellular accumulation of acid soluble metabolites, representing incomplete oxidation of OA. 
D) [1-14C]-OA oxidized to 14CO2 in Plin5+/+ and Plin5− /− cardiomyocytes pre-incubated with either OA or [1-14C]-OA. Cardiomyocytes were incubated with OA for 
18 h prior to incubation with [1-14C]-OA for 2 h (protocol #1), or incubated with [1-14C]-OA for 20 h (protocol #2). For both protocols, 14CO2 was captured for the 
last 2 h (18→20 h). 
E) The figure illustrates how the LD pool seems to affect 14CO2 measurements. Differences in LD content in the presence or absence of Plin5 results in different levels 
of unlabeled OA versus [1-14C]-OA being routed to the mitochondria for oxidation into CO2. 
F) Complete OA oxidation in cardiomyocytes incubated with [1-14C]-OA from time point 0 h (protocol #2). Released 14CO2 was captured for 2 h at indicated time 
points (0 → 2 h, 4 → 6 h, 18 → 20 h) to determine completely oxidized OA. Results are presented as means ± SD in D) and means ± SEM in the rest (n = 4–6. *p < 0.05 
indicate differences between Plin5+/+ and Plin5− /− ; #p < 0.05, indicate differences between vehicle and Atglistatin; †p < 0.05 indicate differences between label-
ling protocols). 
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same age (Fig. 5A). Heart weights of Plin5+/+ and Plin5− /− mice were 
the same at 15 weeks, whereas the weights of Plin5− /− hearts increased 
about 25% from 15 to 55 weeks of age and were significantly higher 
than that of Plin5+/+ hearts at 55 weeks (Fig. 5B). Cardiac expression of 
myosin heavy chain beta (Myh7) mRNA increased with age in both ge-
notypes, and was significantly higher in myocardium of Plin5− /− mice 
compared to Plin5+/+ at 55 weeks of age (Fig. 5C). Expression of myosin 
heavy chain alpha (Myh6) was unaltered by age or by genotype. mRNAs 
of Nppa and Nppb, encoding two natriuretic peptides that usually in-
crease in heart failure, were not different between Plin5+/+ and Plin5− /−
hearts, although Nppb mRNA levels approximately doubled with age 
(Fig. 5C). 
To compare the cardiac metabolic profile of young and old Plin5+/+
and Plin5− /− mice, we measured the stored energy substrates and 
expression of selected metabolic genes in myocardium. As expected, 
cardiac TAG content was lower in Plin5− /− mice compared to Plin5+/+
(Fig. 5D), but increased with age in both genotypes. The variability in 
cardiac glycogen storage was high between individuals, with no clear 
difference between ages or genotypes (Fig. 5F). Plin5− /− hearts showed 
minor changes in gene expression associated with fatty acid and glucose 
metabolisms compared with Plin5+/+ hearts (Fig. 5E and G). Of note, 
Plin5− /− myocardium had slightly upregulated expression of some genes 
responsible for fatty acid uptake (Cd36) and utilization (Fabp4, Cpt1b) in 
old mice, whereas some genes involved in glucose utilization (Hk2 and 
Pdha1) were mainly elevated in myocardium of young Plin5− /− mice. In 
addition, expression of genes encoding glycogen metabolic enzymes 
(Gys1, Gyg, and Gbe1) were slightly elevated in Plin5− /− hearts (Fig. 5H). 
In sum, these modest changes in gene expression would not suggest that 
Fig. 3. Incubation with oleic acid alleviates hypoxia induced damage of Plin5− /− cardiomyocytes. 
Cardiomyocytes were isolated from Plin5+/+ and Plin5− /− mice (16 weeks) and incubated for 16 h in media containing BSA (BSA), 100 μM oleic acid (OA), or 100 μM 
OA and 10 μM Atglistatin (OA þ Atglistatin). Cardiomyocytes were subsequently exposed to normoxia or hypoxia (1% oxygen) for 30 min followed by re‑ox-
ygenation for 20 min. Conditioned media were collected before (16 h), after normoxia/hypoxia (30 min) and after re‑oxygenation (20 min). 
A) LDH released (% of total LDH) from cells exposed to normoxia. 
B) LDH released (% of total LDH) from cells exposed to hypoxia. 
C) Glycogen content in cardiomyocytes after 16 h of incubation. 
Data for LDH measurements is presented as means ± SEM (n = 6) and glycogen content as means ± SD (n = 4. *p < 0.05 indicate differences between Plin5+/+ and 
Plin5− /− cardiomyocytes, #p < 0.01 indicate difference between BSA and other treatments, §p < 0.05 indicate difference between OA and OA+Atglistatin). 
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altered transcriptional signaling remodels myocardium fatty acid and 
glycolytic pathways to a large degree. This is in line with unaltered 
glucose and fatty acid metabolism measured in cultured 
cardiomyocytes. 
4. Discussion 
Plin5 is highly expressed in myocardium and is the dominant lipid 
droplet binding protein in the heart [22–24]. Whole hearts and car-
diomyocytes isolated from Plin5− /− mice store less LDs, especially after 
exposure to elevated levels of fatty acids [25,34,46,54], whereas cardiac 
Plin5 overexpression increases LD content [26,27,46]. In the present 
study, we compared the metabolic properties of Plin5+/+ and Plin5− /−
cardiomyocytes. We showed that Plin5− /− cardiomyocytes stored 
normal levels of LDs when ATGL activity was inhibited. Lack of Plin5 in 
cardiomyocytes did not affect the complete oxidation of OA into CO2, 
but transiently increased intermediate OA metabolites. Plin5− /− car-
diomyocytes pre-incubated with OA maintained more glycogen and 
were more tolerant to hypoxia. The heart weight and cardiac Myh7 
mRNA expression increased with age in Plin5− /− mice, whereas 
expression of genes important for glucose and fatty acid metabolism was 
mostly unaltered. Taken together, our investigation complements pre-
vious studies on Plin5 and supports an important role of Plin5 for cardiac 
LD storage. 
Plin5 overexpression increases cardiac LD content [26,27] whereas 
Plin5 deletion reduces LD storage [25]. In agreement with previous 
findings, we observed that OA-stimulated LD storage was significantly 
reduced in Plin5− /− cardiomyocytes. Impaired storage of OA and LDs in 
Plin5− /− cardiomyocytes were completely restored by inhibiting ATGL, 
the key enzyme of cardiac TAG lipolysis [55]. This is in agreement with 
other reports showing that Plin5 interacts with ATGL and its co-activator 
alpha-beta hydrolase domain-containing 5 to regulate lipolytic rate 
[56,57]. Other studies have suggested that altered fatty acid uptake may 
contribute to the reduced LD levels in Plin5− /− hearts. Uptake of pal-
mitic acid is reduced in hearts of Plin5− /− mice [34] and the same is 
reported for hepatocytes of liver-specific Plin5− /− mice [44]. Although 
altered fatty acid uptake may play a role, our results suggest that 
enhanced lipolysis in the lack of Plin5 is the main factor resulting in the 
depleted LD storage in cardiomyocytes. 
A signal sequence in the C-terminus of Plin5 facilitates physical 
binding between LDs and mitochondria [28]. This binding seems unique 
for Plin5 in the Plin family. Due to the relatively restricted expression of 
Plin5 in oxidative tissues [22–24], Plin5 was initially hypothesized to 
facilitate fatty acid flux into mitochondria to fuel fatty acid oxidation 
[58]. A more recent study, however, suggests that Plin5-mediated 
binding of LDs with mitochondria may provide ATP for the synthesis 
Fig. 4. Heart function and infarct size of ex vivo 
perfused mouse hearts. 
Hearts were isolated from male Plin5+/+ and Plin5− /−
mice (16 weeks) and retrogradely perfused with 
Krebs-Henseleit buffer through the aorta. After sta-
bilization for 20 min, hearts were subjected to 35 min 
of ischemia followed by 60 min of reperfusion. At the 
end of the reperfusion, heart cross sections (1 mm 
thick) were stained with triphenyl tetrazolium chlo-
ride (TTC) to assess infarct size. A) Left ventricular 
systolic pressure (LVSP). B) Left ventricular end- 
diastolic pressure (LVEDP). C) Left ventricular 
developed pressure (LVdeP = LVSP − LVEDP). D) 
Heart rate. E) Rate pressure product (RPP, product of 
C and D). F) Infarct size for in vitro perfused Plin5+/+
and Plin5− /− hearts based on TCC staining where 
viable tissue is shown as red. Each data point gives 
damage percentage of 5 sections per heart. Sections 
1–5 (S1-S5, from the heart atrium toward the apex) 
form one representative for each genotype are shown. 
Heart function data (A-E) is presented as 
means ± SEM, whereas infarct size (F) is presented as 
means ± SD (n = 9. *p < 0.05 indicate differences 
between Plin5+/+ and Plin5− /− hearts).   
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of core lipids to expand LDs [29]. Furthermore, in metabolic flux assays, 
expression of Plin5 is reported to enhance [44,45], reduce [25,46,47], or 
have no effect [48] on fatty acid oxidation. The role of Plin5 for fatty 
acid oxidation is therefore unclear and debated. The discrepant 
observations may be caused by variations in cell types, the fatty acids 
used, or other experimental conditions. In metabolic flux assays using 
radioactive tracers, measured 14CO2 is used to estimate total CO2 pro-
duction [59]. We compared two labelling protocols to estimate fatty acid 
Fig. 5. Plin5− /− mice have increased heart weight with age but mild changes in cardiac metabolism 
Female Plin5+/+ and Plin5− /− mice (15 and 55 weeks) with ad libitum access to chow were analyzed to address differences in heart with aging. A) Body weight. B) 
Heart weight. C) Expression of mRNAs encoding selected myofiber types and natriuretic peptides. D) Cardiac triacylglycerol (TAG) content. E) Relative expression of 
genes involved in fatty acid metabolism. F) Cardiac glycogen content. G) Relative expression of genes involved in glucose metabolism. H) Relative expression of 
genes involved in glycogen metabolism. 
Gene expressions are normalized to the expression of Rplp0 and are presented as means ± SD relative to expression in 15-weeks Plin5+/+ heart (n = 7–8. *p < 0.05, 
**p < 0.005 indicate differences between Plin5+/+ and Plin5− /− ; #p < 0.05, ##p < 0.005 indicate differences with age). Abbreviations: Cd36, CD36 molecule; Cpt1a, 
carnitine palmitoyltransferase 1a; Cpt1b, carnitine palmitoyltransferase 1b; Fabp3, fatty acid binding protein 3; Fabp4, fatty acid binding protein 4; Gbe1, glucan 
(1,4-alpha-) branching enzyme 1; Gyg, glycogenin; Gys1, glycogen synthase 1; Hk1, hexokinase 1; Hk2, hexokinase 2; Myh6, Myosin heavy chain α isoform; Myh7, 
Myosin heavy chain β isoform; Nppa, natriuretic peptide type A; Nppb, natriuretic peptide type B; Pdha1, pyruvate dehydrogenase E1 alpha 1; Pdk4, pyruvate 
dehydrogenase kinase, isoenzyme 4; Pygm, glycogen phosphorylase; Slc2a1, solute carrier family 2 member 1 (Glut1); Slc2a4, solute carrier family 2 member 4 
(Glut4); N.D., not detected. 
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oxidation rate in cardiomyocytes. The production of 14CO2 in Plin5+/+
and Plin5− /− cardiomyocytes was similar after pre-labelling with 14C-OA 
for 18 h. In contrast, production of 14CO2 was higher in Plin5− /− car-
diomyocytes after incubation with unlabeled OA for 18 h. Such obser-
vations suggest that the experimental design is decisive for 
interpretation of oxidative measurements, and may explain the contro-
versy regarding the role of Plin5 for fatty acid oxidation. It is tempting to 
speculate that genotype-driven differences in intracellular LD levels 
prior to 14C metabolic tracing experiments influence such measure-
ments. In our study, a higher fraction of unlabeled OA released from LDs 
in OA pre-incubated Plin5+/+ cardiomyocytes seems to compete with the 
newly added 14C-OA as a substrate for fatty acid oxidation, resulting in 
reduced production of 14CO2 compared to levels measured for Plin5− /−
cardiomyocytes. Furthermore, we observed a transient increase in fatty 
acid metabolic intermediates (acid soluble metabolites) in Plin5− /−
cardiomyocytes during the first few hours of OA-incubation. These 
findings are in agreement with earlier views suggesting that the presence 
of Plin5 reduces LD turnover [60]. Overall, our metabolic flux assays 
suggest that deletion of Plin5 in cardiomyocytes may result in a 
disturbed fatty acid β-oxidation, but do not affect the downstream ca-
pacity of mitochondrial oxidative phosphorylation and CO2 production. 
This conclusion is supported by examination of young and old Plin5+/+
and Plin5− /− mice, where we observed essentially no obvious difference 
in the expression of genes important for glucose and fatty acid oxidation 
between Plin5+/+ and Plin5− /− hearts. 
Mice lacking Plin5 in all tissues have increased infarct size and 
higher mortality following in vivo myocardial infarction [34,61]. How-
ever, systemic alterations caused by Plin5 deletion in other tissues may 
contribute to the altered cardiac metabolism, heart function and sus-
ceptibility to ischemia/hypoxia [47,62,63], confounding our under-
standing on the cardiac-specific role of Plin5 per se during myocardial 
ischemia. Alternatively, factors external to cardiomyocytes and pro-
duced independently of Plin5 may influence hearts of Plin5+/+ and 
Plin5− /− mice differentially. Our ex vivo heart and isolated car-
diomyocyte models have such systemic interactions excluded [37]. The 
infarct size was similar in ex vivo perfused hearts from Plin5+/+ and 
Plin5− /− mice. In this model, it might be that the Plin5− /− phenotype 
was masked by the absence of exogenous fatty acids. This result is in 
contrast to the previously reported protective effects of Plin5 during 
cardiac ischemia in vivo [34,61]. Still, when isolated cardiomyocytes 
were pre-treated with OA, we did observe protective effects in Plin5− /−
cardiomyocytes during hypoxia. 
It has been suggested that LDs may protect cardiomyocytes from 
ischemia-reperfusion injury by preventing excessive cytosolic levels of 
free fatty acids and Ca2+ [33]. However, OA stimulated LD-deficient 
Plin5− /− cardiomyocytes had less damage compared to OA stimulate 
LD-rich Plin5+/+ cardiomyocytes. Thus, our results are not consistent 
with a simple protective role for accumulated LDs in cardiomyocytes 
prior to hypoxia. Instead, we speculate that factors other than just LD 
content may have influenced hypoxia-induced damage in car-
diomyocytes. During hypoxia, cardiomyocytes must rely on anaerobic 
metabolism for ATP production. This is achieved through conversion of 
glucose or other energy substrates into pyruvate, followed by conversion 
of pyruvate to lactate [53,64]. Therefore, the glycogen content of car-
diomyocytes and the ability to use alternative energy sources are 
important for cell viability during hypoxia. Metabolic flux assays suggest 
that glucose accumulation and glucose oxidation were similar in isolated 
Plin5+/+ and Plin5− /− cardiomyocytes. Still, a higher glycogen content 
was detected in Plin5− /− cardiomyocytes exposed to OA. This suggests 
that hypoxia-induced damage might be reduced by preservation of the 
glycogen storage in Plin5− /− cardiomyocytes. 
Previous studies suggest that heart function declines with age in 
Plin5− /− mice [25]. In our study, heart weight and cardiac Myh7 mRNA 
levels increased slightly in aged Plin5− /− mice. Expression of Nppa and 
Nppb mRNAs, two biomarkers of heart failure [65–67], was not affected 
by genotype. Expression of certain genes important for fatty acid and 
glucose oxidation were altered by age, but were essentially similarly 
expressed in Plin5+/+ and Plin5− /− hearts. Although no detailed inves-
tigation on heart function was performed in young and old mice, 
enlargement of the Plin5− /− heart with age seems not to involve altered 
capacity to metabolize glucose or fatty acids. Plin5 deficiency seems to 
cause myocardial remodeling that may influence heart failure with age, 
but based on other reports, this seems to depend on cardiac stress levels 
[34,61]. 
In summary, our results suggest that Plin5 deficient cardiomyocytes 
have an impaired ability to store LDs due to enhanced ATGL catalyzed 
lipolysis. The reduced LD storage decreased the capacity to sequester 
cytosolic fatty acids in Plin5− /− cardiomyocytes, but without signifi-
cantly changing the rate of complete fatty acid oxidation. Accumulation 
of cardiac LDs per se does not seem to have a major protective effect on 
hypoxic damage in isolated cardiomyocytes. Although pretreatment 
with OA preserved glycogen storage and improved tolerance to hypoxia 
in Plin5− /− cardiomyocytes, our results underscore a complex interre-
lationship among heart and other tissues in the role of LD and glycogen 
storage/metabolism during ischemia. 
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